GSK-2849466

GSK-2849466
Clinical data
Drug class	Selective androgen receptor modulator
Identifiers
	IUPAC name 2,3-dichloro-4-[[(2S)-3-hydroxy-3-methylbutan-2-yl]amino]benzonitrile;
CAS Number	2865213-83-6;
PubChem CID	162623750;
UNII	G6UPC5EU71;
Chemical and physical data
Formula	C12H14Cl2N2O
Molar mass	273.16 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C(C)(C)O)NC1=C(C(=C(C=C1)C#N)Cl)Cl;
	InChI InChI=InChI=1S/C12H14Cl2N2O/c1-7(12(2,3)17)16-9-5-4-8(6-15)10(13)11(9)14/h4-5,7,16-17H,1-3H3/t7-/m0/s1; Key:KYBPRVBQMUAOFG-ZETCQYMHSA-N;

GSK-2849466 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK). This experimental compound reached Phase I clinical trials for the treatment of cachexia and heart failure.^[1]^[2]^[3] However, as of February 2014, GSK discontinued the development of GSK-2849466 for both indications after completing Phase I studies.^[2]

References

^ "GSK-2849466". PatSnap.
^ ^a ^b "GSK 2849466". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 2024-01-14. Retrieved 2024-01-14.
^ Fonseca GW, Dworatzek E, Ebner N, Von Haehling S (August 2020). "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs. 29 (8): 881–891. doi:10.1080/13543784.2020.1777275. PMID 32476495.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.